LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
14 juin 2024 11h00 HE
|
Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...